Ann Lab Med.  2023 Jan;43(1):96-99. 10.3343/alm.2023.43.1.96.

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab

• Lee MY
• Lee WI
• Kang SY
• Kim MH
• Park YS

• KMID: 2551609
• DOI: http://doi.org/10.3343/alm.2023.43.1.96

Figure

• 

  Fig. 1 Regression graphs and Bland–Altman plots of FVIII assay: (A, B) for ACL TOP OSA vs. CN-6000 OSA, (C, D) for ACL TOP OSA vs. CN-6000 CSA, and (E, F) for CN-6000 OSA vs. CN-6000 CSA in the hemophilia patient group (excluding samples receiving non-factor treatment).

Reference

1. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. 2016; Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 374:2044–53. DOI: 10.1056/NEJMoa1511769. PMID: 27223146.

2. Bowyer A, Kitchen S, Maclean R. 2020; Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia. 26:536–42. DOI: 10.1111/hae.13990. PMID: 32249990.

3. Administration FaD. HEMLIBRA (emicizumab-kxwh) injection for subcutaneous use, prescribing information. In: Administration FaD, ed. Initial U.S.;2017.

4. Jenkins PV, Bowyer A, Burgess C, Gray E, Kitchen S, Murphy P, et al. 2020; Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 26:151–5. DOI: 10.1111/hae.13903. PMID: 31859415.

5. Nougier C, Jeanpierre E, Ternisien C, Proulle V, Hezard N, Pouplard C, et al. 2020; Emicizumab treatment: impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals). Eur J Haematol. 105:675–81. DOI: 10.1111/ejh.13490. PMID: 32668090.